Technology | June 09, 2014

Personalized Care from Disease Detection through Treatment Assessment Enabled with GE Healthcare’s Discovery IQ

June 9, 2014 — At the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE Healthcare introduced its Discovery* IQ^ PET/CT (positron emission tomography/ computed tomography) system enabling both outstanding image quality and intelligent quantitation, helping physicians to deliver the best possible patient outcomes.

Discovery IQ

Physicians not only want the ability to detect smaller lesions, but also the ability to determine earlier whether the patient is responding to current treatment. With the highest sensitivity in the industry (up to 22 cps/kBq), the largest axial field-of-view (up to 26 cm) and quantitative SUV measurements physicians can trust, Discovery IQ provides an essential tool to delivering personalized patient care. It enables physicians with the ability to see smaller lesions, scan faster with lower dose and improved image quality, read more efficiently and reach more patients.

“By 2020, it’s estimated that 50 percent of people will develop cancer at some point in their lives and we also know that currently approximately 70 percent of cancer patients do not respond to their initial chemotherapy treatment,” said Steve Gray, president and CEO of GE Healthcare MICT. “I’m excited to introduce the Discovery IQ to help physicians with their primary mission of delivering the best possible patient outcomes. And, we’ve focused on designing the system to make it as accessible as possible to more people in more places, to ensure high-performance PET/CT clinical care is available to whomever needs it.”

Some key innovative features of Discovery IQ include:

  • GE Healthcare’s Q.Clear PET reconstruction technology, providing up to 2x improvement in both image quality and quantitation accuracy.
  • A fully scalable system, allowing for the ability to upgrade as department needs change.
  • This platform will be available also for the mobile market — enabling the latest technology across both fixed and mobile environments.
  • The new platform design and the new LightBurst detector technology allow for whole organ imaging via fast scans at low dose to help maximize patient comfort and safety.
  • Fast electronics and a dual acquisition channel that enables high quantitative accuracy for all clinically relevant tracers.

“As a leading U.S. academic institution with a strong international interest in oncology services, our mission is to provide high quality care to patients close to home,” said Charles Bogosta, president of UPMC’s international and commercial services division. “We are excited to see GE’s vision of quality, affordability and access so well aligned with ours in this regard.”

Q.Clear

GE Healthcare’s Q.Clear technology is a critical component of Discovery IQ. It delivers, for the first time, no trade-off between image quality and quantitative SUV measurements. By providing two times improvement in both quantitative accuracy and image quality in PET/CT imaging, this innovative new tool provides benefits to physicians across the cancer care continuum from diagnosis, staging, and treatment planning, to treatment assessment. Over the last decade, PET image reconstruction technology has been designed to provide better image quality, reduced acquisition time and lower injected dose. Current PET iterative reconstruction technologies, such as Time of Flight (TOF) and OSEM, force a compromise between image quality and quantitation. GE Healthcare’s new Q.Clear technology shows the advantage of full convergence PET imaging with no compromise between quantitation and image quality.

CortexID Suite^

CortexID software has been developed to aid physicians in the evaluation of patient pathologies via assessment and quantification of PET brain scans. The software aids in the assessment of human brain PET scans enabling automated analysis through quantification of tracer uptake and comparison with the corresponding tracer uptake in normal subjects. The resulting quantification is presented using volumes of interest, voxel-based or 3-D stereotactic surface projection maps of the brain. The package allows the user to generate information regarding relative changes in PET-FDG glucose metabolism and in PET brain amyloid load between a subject’s images and a normal database, which may be the result of brain neurodegeneration.

For more information: newsroom.gehealthcare.com

*Trademark of General Electric Co.

^ 510(k) pending at FDA. Not available for sale in the United States. Not for sale in all regions.

Related Content

Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
Blood clots in veins and arteries can lead to heart attack, stroke and pulmonary embolism, which are major causes of...
PET imaging, atherosclerotic plaque, inflammation, Ga-68-pentixafor, Technishe Universitat Munchen, Germany

Note the high uptake of Ga-68-pentixafor on multi-planar reconstructions in the organs expressing CXCR4 such as the spleen (red arrows) and adrenal glands (yellow arrows), which was nearly completely blocked by the pre-injection of AMD 3100, a potent CXCR4 inhibitor. Strong accumulation of Ga-68-pentixafor was also found in the kidneys (asterisks) reflecting the renal clearance of the tracer. In addition, high, focal activities were detected in the abdominal aorta (red arrowheads) and right carotid artery (orange arrowheads) of atherosclerotic rabbits, whereas no significant signal could be detected in the non-injured left carotid artery (white arrowheads) of atherosclerotic and control rabbits, as well as in the abdominal aorta and right carotid artery of control rabbits. Furthermore, focal activities detected with PET in atherosclerotic plaques of the abdominal aorta and the right carotid artery decreased significantly when the same rabbit was re-imaged after blocking CXCR4 receptors. Image courtesy of Fabien Hyafil, M.D., Ph.D., Department of Nuclear Medicine, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany

News | PET Imaging | March 03, 2017
In the featured article of the March 2017 issue of The Journal of Nuclear Medicine, researchers demonstrate that a new...
ASNC, SNMMI, position statement, myocardial perfusion PET, coronary artery disease
News | PET Imaging | September 01, 2016
September 1, 2016 — The American Society for Nuclear Cardiology (ASNC) and the Society of...
cardiac PET, myocardial perfusion, PET-CT, cardiac perfusion

A PET-CT cardiac perfusion exam from a Siemens Biograph scanner. The black and white areas of the image show the CT imaging of the anatomy. The colored portion shows the PET overlay on the myocardium and is color-coded to show tracer uptake values. This can show areas of the heart muscle where there are perfusion defects cause by infarcts or coronary artery blockages due to a heart attack and help determine the severity of the ischemia.

Feature | PET Imaging | June 03, 2016 | Dave Fornell
Positron emission tomography (PET) is a nuclear imaging technology (also referred to as molecular imaging) that enabl
blood clot detection, single scan, rats, radionuclides, Peter Caravan, whole body

The whole body of a rat can be imaged for blood clots with one PET scan (which is overlaid here on an MRI image) using the FBP8 probe. Arrow points to a blood clot. Image courtesy of Peter Caravan, Ph.D.

News | PET Imaging | September 23, 2015
September 23, 2015 — New research de
Overlay Init